Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2020.05.19.20101832: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Consent: Following informed consent, participants completed a questionnaire which covered sociodemographic information, underlying medical conditions, and details related to SARSCoV-2 infection, including date of testing, date of symptom onset and a description of symptoms. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources Serologic response measurement: All serum samples were tested for antibody responses to SARS-CoV-2 using two serologic assays: 1) a rapid immunodiagnostic assay detecting SARS-CoV-2 spike protein receptor binding domain (RBD) … SciScore for 10.1101/2020.05.19.20101832: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Consent: Following informed consent, participants completed a questionnaire which covered sociodemographic information, underlying medical conditions, and details related to SARSCoV-2 infection, including date of testing, date of symptom onset and a description of symptoms. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources Serologic response measurement: All serum samples were tested for antibody responses to SARS-CoV-2 using two serologic assays: 1) a rapid immunodiagnostic assay detecting SARS-CoV-2 spike protein receptor binding domain (RBD) developed by Biosynex®; 2) the S-Flow assay, a flow-cytometry based assay that measures antibodies binding to the Spike protein (S) expressed at the surface of target cells [8]. SARS-CoV-2 spike protein receptor binding domain (RBDsuggested: NoneStatistical analyses: Seropositivity was defined as the presence of detectable anti-SARS-CoV-2 antibodies. anti-SARS-CoV-2suggested: NoneSoftware and Algorithms Sentences Resources All analyses were performed using Stata (Stata Corp., College Station, Texas, USA) or GraphPad Prism 8 (GraphPad Software, LLC). GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)GraphPadsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04325646 Recruiting Sero-epidemiological Study of the SARS-CoV-2 Virus Responsib… Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a protocol registration statement.
-
-